Dexcom (NSDQ:DXCM) shares jumped after hours today on third-quarter results that bettered the consensus forecast. The San Diego–based continuous glucose monitoring system developer posted profits of $45.8 million, or 50¢ per share, on sales of $396.3 million for the three months ended Sept. 30, for a 1.7% bottom-line slide on sales growth of 48.6%. Adjusted to […]
Insulet Q3 earnings beat The Street despite bottom-line slide
Insulet (NSDQ:PODD) shares are rising today on third-quarter results that topped the consensus forecast, despite a dip in profits. The Acton, Mass.–based company posted profits of $852,000, or 1¢ per share, on sales of $192.1 million for the three months ended Sept. 30, for a 48.6% bottom-line slide on sales growth of 27.1%. Get the full […]
Insulet wins FDA nod for Omnipod with Novo Nordisk’s Fiasp insulin
Insulet (NSDQ:PODD) said last week that it won FDA clearance for the use of Novo Nordisk‘s (NYSE:NVO) Fiasp insulin with the Omnipod insulin management platform. Acton, Mass.-based Insulet said it completed extensive testing to ensure that Fiasp is safe and usable with the Omnipod and Omnipod Dash systems. It’s the first insulin pump in the U.S. […]
Senseonics touts Humana reimbursement nod for Eversense CGM
Senseonics (NYSE:SENS) said yesterday that Humana is now providing coverage for its Eversense continuous glucose monitoring system and insertion procedure. Humana is the fifth-largest health insurer in the U.S. with 17 million patients in 50 states, Washington, D.C. and Puerto Rico, according to a news release. Its coverage policy with Senseonics makes patients with Type 1 […]
FDA OKs Novo Nordisk’s Fiasp for infusion pumps
Novo Nordisk (NYSE:NVO) said today that it won an expanded label from the FDA for its Fiasp fast-acting insulin aspart injection for use with infusion pumps by adults with Type 1 or Type 2 diabetes. Fiasp won FDA approval in 2017 for use in intravenous infusion under professional supervision or by subcutaneous multiple daily injection in […]
Livongo inks deal with BCBS Kansas City
Livongo Health (NSDQ:LVGO) said yesterday that it expanded its partnership with Blue Cross & Blue Shield of Kansas City to offer its diabetes program to all of Blue KC’s fully insured clients. The agreement intends to make Livongo available to eligible administrative services only clients with Blue KC as well, according to a news release. Blue […]
NIH study: Tandem Diabetes artificial pancreas bests other treatments
A pivotal trial funded by the National Institutes of Health found that an artificial pancreas system from Tandem Diabetes Care (NSDQ:TNDM) was more effective than existing treatments for people with Type 1 diabetes. The Tandem system combines its t:slim X2 insulin pump and Control-IQ advanced hybrid closed-loop technology with a continuous glucose monitor made by DXCM, […]
Senseonics touts Eversense reimbursement win
Senseonics (NYSE:SENS) said this week that Health Care Service Corporation – Blue Cross Blue Shield is providing coverage for the Eversense continuous glucose monitoring system, effective as of yesterday. HCSC – Blue Cross Blue Shield is the fourth-largest health insurer in the U.S. and serves more than 16 million members, according to a news release. Last […]
Intarcia Therapeutics takes another run at FDA approval
Intarcia Therapeutics said last week that the FDA accepted its new drug application resubmission for ITCA 650 for the treatment of Type 2 diabetes mellitus. The Boston-based company originally resubmitted the NDA on Sept. 9. FDA told the company that it considered the NDA resubmission a complete class 2 response. The Prescription Drug User Fee Act […]
How Medtronic could help change healthcare for the better
Medtronic officials want the world’s largest medtech company to do more than just make medical devices: They want to help manage chronic diseases. Here are thoughts from the VP helping to lead the shift. Medtronic executive Sheri Dodd had a cousin — one of only four — die from Type 2 diabetes complications at the age […]
Abbott inks inks diabetes tech partnerships with Tandem Diabetes, Omada Health
Abbott (NYSE:ABT) said today that it has entered into an agreement with Tandem Diabetes Care (NSDQ:TNDM) to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The news comes one day after Abbott announced a partnership with Omada Health to pair Abbott’s FreeStyle Libre continuous glucose monitoring system with Omada’s digital care program. Get the full story at our […]
- 1
- 2
- 3
- …
- 86
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube